CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

J&J, AbbVie said to have also looked at AtaiBeckley before Lilly’s $2.8B deal

Neutral
AI Analysis

Summary

Eli Lilly completed a $2.8B acquisition of AtaiBeckley, a psychedelic-focused biotech company. Johnson & Johnson and AbbVie also considered the deal but did not submit offers.

Importance:7/10
Sentiment:
0.00
M&Apsychedelicsacquisition
Related Companies

Read the original article

Published by Endpoints News on July 20, 2026 3:03 PM

Read Original